Gene synthesis is the quiet commercial engine at the center of the “Imperium” pitch. It is the service of writing custom DNA sequences to order, turning a string of letters a scientist types on a screen into physical DNA that shows up in a tube a few days later. For Adam O’Dell’s thesis, this is the write step of the DNA-as-software story, and it is the step where one company, Twist Bioscience (TWST), sits as the pitch’s silicon-layer pick. Here is how the service works, what it costs, and where the honest caveats live.
What Is Gene Synthesis?
Gene synthesis is the opposite of reading DNA. Where sequencing decodes an existing sequence, synthesis builds a new one from scratch. A customer specifies the exact order of the four chemical bases, A, C, G, and T, and the vendor prints that sequence as a physical strand of DNA the customer can then put to work in a cell, a diagnostic, or a research project.
The service exists because nature is slow and limited. Instead of searching for a naturally occurring gene or mutating an organism and hoping, a researcher can simply order the precise sequence the project needs. That makes synthesis the backbone of modern drug discovery, agricultural engineering, and industrial biotech, and it is why the Imperium pitch frames the whole field around the ability to “write the code of living things.”
How the Workflow Works
The process starts with a digital sequence. A scientist designs the DNA they want, sometimes with AI assistance, and submits the sequence to a vendor. The vendor then assembles that sequence from short chemical building blocks, stitching them together into longer strands, verifying the result, and shipping it back. The price scales with length and complexity, so a short gene costs less than a long one, and a sequence with tricky or repetitive regions costs more than a clean one.
This is a manufacturing business at heart, and its economics look a lot like other precision manufacturing: throughput, yield, and error rates decide who wins. The companies that can print longer, more accurate DNA at lower cost take share, which is exactly the curve the pitch is betting on. For a fuller walk-through of the write step itself, see our DNA synthesis explainer.
Twist Bioscience and the Silicon-Chip Claim
Twist Bioscience is the name the pitch puts at the center of this market. Twist’s NanoWell technology synthesizes DNA on silicon chips rather than in the traditional plastic plates, packing thousands of tiny wells onto a single chip so many sequences can be built in parallel. The pitch’s version of the advantage is a single, bold sentence: Twist “processes DNA at 10,000 times the speed of the previous technology.”
That is a genuine technological difference, and the chip approach really is a step change in how much DNA can be produced in one run. Twist’s customer and partner list reflects it, with names like Amazon, Microsoft, Johns Hopkins, Illumina, and DARPA attached to the company’s work. The financials underneath are steady, too: fifteen consecutive quarters of roughly 20% revenue growth, a market cap near $7.6 billion, and a position near break-even on an adjusted cash-flow basis.
The Economics, and the Honest Caveat
The honest caveat sits on that headline number. The “10,000 times faster” figure is a marketing number that our teardown could not independently verify, and it should be read as directional rather than precise. The underlying trend, that DNA synthesis keeps getting cheaper and faster, is broadly true and well documented. The specific multiple is the part to treat with care.
Valuation is the other caveat, and it is the one investors will feel most directly. Twist trades at a premium in a competitive tools market, and that premium has drawn real skepticism: BWS Financial initiated coverage with a Sell rating and a $45 target, arguing the stock has run ahead of the business. For the full financial picture, including the analyst debate, see our Twist Bioscience stock piece.
Where Gene Synthesis Sits in the Imperium Thesis
In O’Dell’s three-layer stack, gene synthesis is the silicon layer, and it is the layer the whole thesis depends on. If writing DNA becomes as cheap and routine as printing a document, then the software and apps layers built on top of it become valuable in the way Windows and its applications became valuable on top of Intel chips.
That is the core bet, and it is a reasonable one to make in the long run. The write step is real, the demand is real, and the technology is genuinely improving. What an investor has to decide is not whether gene synthesis matters, but whether any single company, at any single price, is the right way to own it. The market piece on the category, gene synthesis market explained, covers the broader competitive picture.
A Market That Keeps Compounding
The market itself is the least controversial part of the story. Demand for synthetic DNA grows with every new drug program, diagnostic, and agricultural trait, and the buyers, from Amazon to Eli Lilly, are large and well funded. The question an investor has to answer is not whether the market grows, but which supplier, at which price, is the right way to own that growth.
Ready to see the research? Click here to access Adam O’Dell’s report.
NewsletterVetter is an independent publication. We receive compensation from some of the services we review through affiliate links. Nothing on this site is investment advice. Always do your own research.